Tirzepatide holds potential to outperform oral and injectable semaglutide for glycemic control and weight-loss in T2D, says GlobalData

Eli Lilly’s Mounjaro (tirzepatide) was more effective than both Novo Nordisk’s injectable Ozempic and oral Rybelsus (semaglutide) in helping adults with type 2 diabetes (T2D) achieve glycemic and weight-loss targets, according to real-world evidence presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results highlight tirzepatide’s potential to address […]